LEO LABORATORIES LIMITED

LEO Pharma launches Anzupgo (delgocitinib) cream in Germany for moderate to severe chronic hand eczema, following EC approval. Anzupgo is a topical JAK inhibitor addressing unmet needs, with phase 3 trials showing efficacy and safety. Germany is the first country to offer this treatment, with regulatory filings ongoing in other markets.

The Pink Sheet's EU centralized approvals list updated with four new products, including Anzupgo by LEO Pharma for moderate to severe chronic hand eczema in adults.

Germany is the first country to launch Anzupgo, a topical treatment for moderate to severe Chronic Hand Eczema (CHE) where topical corticosteroids are inadequate or inappropriate. This new treatment addresses a significant unmet need for the estimated 3.9 million people in Germany living with CHE.

LEO Pharma launches delgocitinib (Anzupgo) cream in Germany, the first country to offer the treatment for moderate to severe chronic hand eczema (CHE). The European Commission approved delgocitinib for patients unresponsive to topical corticosteroids, applicable across EU member states, Norway, Iceland, and Liechtenstein. The decision was based on phase 3 DELTA trials showing significant improvements in clinical symptoms, with DELTA 3 extension trial demonstrating long-term safety and sustained efficacy.

Leo Pharma launches JAK inhibitor Anzupgo in Germany.

Germany debuts LEO Pharma's Anzupgo, the first topical treatment for chronic hand eczema (CHE), with a list price of €953.25. Anzupgo, a pan-JAK inhibitor, outperformed placebo in phase 3 trials, showing better symptom relief. LEO plans further launches, aiming for revenue growth from 2025.

Leo Pharma's fourth job cuts in two years could impact the company, according to HR specialist Morten Ballisager.

Eli Lilly’s Ebglyss (lebrikizumab) gains US approval for atopic dermatitis (AD), offering a new therapeutic option for patients with limited success from existing treatments. Ebglyss’s clinical trials demonstrated efficacy and tolerance, positioning it as a competitor to Dupixent and Adbry/Adtralza. Comparative studies suggest lebrikizumab may offer equal or superior long-term efficacy and less frequent dosing. Ebglyss’s market success will depend on differentiation, strategic positioning, and real-world clinical benefits.

Eli Lilly’s Ebglyss (lebrikizumab) approval in the US positions it competitively in the atopic dermatitis market, offering a therapeutic option for patients with limited success from existing treatments. Ebglyss selectively targets IL-13, potentially providing equal or superior long-term efficacy with less frequent dosing compared to Dupixent and Adbry/Adtralza. Its success will depend on differentiation, strategic positioning, and real-world clinical benefits.